Hemophilia B: Updates from 2018 American Society of Hematology Annual Meeting (ASH 2018)

Description

Hemophilia B can be defined as the genetic disease caused by mutation of one of the genes for coagulation proteins leading to dangerous and uncontrolled bleeding. All those hematologists, primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists who practice hematology and have the interest to treat patients with hemophilia B can switch to the American Society of Hematology Annual Meeting (ASH 2018). Gain online access and learn more about gene therapy and its impact on hemophilia B therapy. In addition to this, also find how immune modulation therapy can be used to induce immune tolerance to Factor IX inhibitors.